



# ECIBC recommendation on breast cancer screening intervals

## Bibliography

### Evidence of effects

Braithwaite, D. Breast Cancer Surveillance, Consortium. (2013). Screening outcomes in older US women undergoing multiple mammograms in community practice: does interval, age, or comorbidity score affect tumour characteristics or false positive rates? *J Natl Cancer Inst*, 105(5), 334-341.

Breast Screening Frequency Trial, Group. (2002). The frequency of breast cancer screening: results from the UKCCCR Randomised Trial. United Kingdom Co-ordinating Committee on Cancer Research. *Eur J Cancer*, 38(11), 1458-1464

Coldman, A. J., (2008). Impact of changing from annual to biennial mammographic screening on breast cancer outcomes in women aged 50-79 in British Columbia. *J Med Screen*, 15(4), 182-187

Dittus K. Impact of mammography screening interval on breast cancer diagnosis by menopausal status and BMI. *J Gen Intern Med* 28(11):1454-62.

Duffy, SW. (2008). Long term mortality results from the UK screening frequency trial in 6th European Breast Cancer Conference: Berlin, Germany.

Habbema J.D.F. Age-specific reduction in breast cancer mortality by screening: an analysis of the results of the Health Insurance Plan of Greater New York Study. *JNCI* 1986; 77:317-320

Hunt, K. A., Rosen, E. L., & Sickles, E. A. (1999). Outcome analysis for women undergoing annual versus biennial screening mammography: a review of 24,211 examinations. *AJR Am J Roentgenol*, 173(2), 285-289

Kerlikowske, K. Breast Cancer Surveillance, Consortium. (2013). Outcomes of screening mammography by frequency, breast density, and postmenopausal hormone therapy. *JAMA Intern Med*, 173(9), 807-816

Klemi, P. J., Toikkanen, S., Rasanen, O., Parvinen, I., & Joensuu, H. (1997). Mammography screening interval and the frequency of interval cancers in a population-based screening. *Br J Cancer*, 75(5), 762-766

Mandelblatt J. Collaborative modeling of the benefits and harms associated with different U.S. breast cancer screening strategies. *Ann Intern Med*. 2016; 164:215-225.

Miglioretti D. Breast tumor prognostic characteristics and biennial vs annual mammography, age, and menopausal status. *JAMA Oncol*. 2015;1(8):1069-1077.

Miglioretti J. Radiation-induced breast cancer incidence and mortality from digital mammography screening. *Ann Intern Med*. 2016; 164:205-214.

Miller A. Twenty five year follow-up for breast cancer incidence and mortality of the Canadian National Breast Screening Study: randomised screening trial. *BMJ* 2014; 348: g366

- Moss S. Effect of mammographic screening from age 40 years on breast cancer mortality at 10 years' follow-up: a randomised controlled trial. *Lancet Oncol* 2015; 16 :1123-32
- Nystrom L. Long-term effects of mammography screening: updated overview of the Swedish randomised trials. *Lancet* 2002; 359: 909-19
- O'Meara, E. (2013). Mammographic screening interval in relation to tumour characteristics and false-positive risk by race/ethnicity and age. *Cancer*, 119(22), 3959-3967
- Parvinen, I., Chiu, S., Pylkkanen, L., Klemi, P., Immonen-Raiha, P.(2011). Effects of annual vs triennial mammography interval on breast cancer incidence and mortality in ages 40-49 in Finland. *Br J Cancer*, 105(9), 1388-1391. doi: 10.1038/bjc.2011.372
- Tabar L. The Swedish two-county trial twenty years later. *Radiol Clin North Am* 2000; 4: 625-51
- Tsunematsu, M., (2015). An analysis of mass screening strategies using a mathematical model: comparison of breast cancer screening in Japan and the United States. *J Epidemiol*, 25(2), 162-171
- Vilapriño, E. Interval Cancer Study, Group. (2014). Cost-effectiveness and harm-benefit analyses of risk-based screening strategies for breast cancer. *PLoS One*, 9(2), e86858.
- Yaffe, M. . (2011). Risk of radiation-induced breast cancer from mammographic screening. *Radiology*, 258(1), 98-105
- Yaffe, M. J. (2015). Clinical outcomes of modelling mammography screening strategies. *Health Rep*, 26(12), 9-15.

### **Acceptability**

No systematic review was carried out

### **Economic Evidence**

- Carles M, Vilapriño E, Cots F, Gregori A, Pla R, Román R, Sala M, Macià F, Castells X, Rue M. Cost-effectiveness of early detection of breast cancer in Catalonia (Spain). *BMC Cancer*. 2011 May 23; 11: 192.
- Gocgun Y, Banjevic D, Taghipour S, Montgomery N, Harvey BJ, Jardine AK, Miller AB. Cost-effectiveness of breast cancer screening policies using simulation. *Breast*. 2015; 24(4): 440-8.
- Rojnik K, Naversnik K, Mateović-Rojnik T, Primiczakelj M. Probabilistic cost-effectiveness modeling of different breast cancer screening policies in Slovenia. *Value Health*. 2008 Mar-Apr; 11(2): 139-48.
- Vilapriño E, Forné C, Carles M, Sala M, Pla R, Castells X, Domingo L, Rue M; Interval Cancer (INCA) Study Group. Cost-effectiveness and harm-benefit analyses of risk-based screening strategies for breast cancer. *PLoS One*. 2014; 9(2): e86858.

### **Values and preferences**

JRC Technical Report PICO 10-11, contract FWC443094012015; available upon request.